Laurion Capital Management LP Purchases 17,971 Shares of Medtronic plc (NYSE:MDT)

Laurion Capital Management LP increased its holdings in shares of Medtronic plc (NYSE:MDT - Free Report) by 24.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 91,374 shares of the medical technology company's stock after buying an additional 17,971 shares during the quarter. Laurion Capital Management LP's holdings in Medtronic were worth $7,299,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Wealth Enhancement Advisory Services LLC lifted its position in Medtronic by 1.2% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 365,780 shares of the medical technology company's stock worth $29,219,000 after buying an additional 4,371 shares in the last quarter. Graypoint LLC grew its stake in Medtronic by 7.6% in the fourth quarter. Graypoint LLC now owns 6,934 shares of the medical technology company's stock valued at $554,000 after purchasing an additional 490 shares in the last quarter. Czech National Bank increased its position in Medtronic by 6.4% in the 4th quarter. Czech National Bank now owns 278,065 shares of the medical technology company's stock worth $22,212,000 after purchasing an additional 16,786 shares during the last quarter. Clark & Stuart Inc purchased a new stake in shares of Medtronic during the 4th quarter worth about $509,000. Finally, Fiduciary Alliance LLC purchased a new stake in shares of Medtronic during the 4th quarter worth about $470,000. 82.06% of the stock is owned by institutional investors and hedge funds.

Medtronic Stock Performance

Shares of Medtronic stock traded up $1.71 during trading on Thursday, reaching $85.96. The company's stock had a trading volume of 6,511,808 shares, compared to its average volume of 6,742,913. Medtronic plc has a one year low of $75.96 and a one year high of $96.25. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.39 and a current ratio of 1.90. The firm has a market cap of $110.25 billion, a price-to-earnings ratio of 26.13, a price-to-earnings-growth ratio of 2.22 and a beta of 0.81. The business's fifty day moving average price is $86.22 and its 200-day moving average price is $86.70.

Medtronic (NYSE:MDT - Get Free Report) last released its earnings results on Tuesday, February 18th. The medical technology company reported $1.39 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.36 by $0.03. Medtronic had a return on equity of 14.07% and a net margin of 12.83%. The firm had revenue of $8.29 billion for the quarter, compared to analyst estimates of $8.33 billion. As a group, equities research analysts predict that Medtronic plc will post 5.46 earnings per share for the current year.

Medtronic Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, April 11th. Investors of record on Friday, March 28th were paid a dividend of $0.70 per share. The ex-dividend date of this dividend was Friday, March 28th. This represents a $2.80 annualized dividend and a yield of 3.26%. Medtronic's dividend payout ratio is 85.11%.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Needham & Company LLC reissued a "hold" rating on shares of Medtronic in a research note on Wednesday, February 19th. Robert W. Baird increased their price target on shares of Medtronic from $90.00 to $91.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 19th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $105.00 price objective on shares of Medtronic in a research note on Wednesday, February 19th. Truist Financial decreased their price objective on shares of Medtronic from $93.00 to $90.00 and set a "hold" rating for the company in a report on Friday, April 11th. Finally, UBS Group raised their target price on Medtronic from $85.00 to $95.00 and gave the company a "neutral" rating in a report on Wednesday, February 19th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Medtronic presently has an average rating of "Hold" and an average price target of $96.14.

Medtronic Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.